Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 52 of 52 entries
View as:
Phase: N/A
Priority: Normal
Start: 10/20/22
End: 12/31/24
Due: 12/31/25
Phase: N/A
Priority: Normal
Start: 12/11/22
End: 12/31/27
Due: 12/31/28
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| The Aim of This Study is to Investigate the Correlation Between the Severity of Glaucoma and Corneal Biomechanics as Well as Anterior Chamber Parameters. | NCT06340061 | Henan Provincial People's Hospital | user2@example.com | None | 2022-10-20 | 2024-12-31 | 2025-12-31 | - | - | 2025-07-14 |
| Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma | NCT05502991 | Henan Provincial People's Hospital | user2@example.com | None | 2022-12-11 | 2027-12-31 | 2028-12-31 | - | - | 2025-07-14 |